{"id":"continuous-pd-1-inhibitor-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL1474985","moleculeType":"Small molecule","molecularWeight":"476.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 inhibitors work by binding to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells. This blockade restores T cell activation and proliferation, enabling the immune system to recognize and attack cancer cells. Continuous dosing aims to maintain sustained immune checkpoint inhibition compared to standard intermittent schedules.","oneSentence":"Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:32.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific tumor type under investigation in Canadian Cancer Trials Group phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT02821013","phase":"PHASE3","title":"Duration of Anti-PD-1 Therapy in Metastatic Melanoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2016-10-31","conditions":"Unresectable/Metastatic Melanoma","enrollment":614},{"nctId":"NCT03491683","phase":"PHASE1, PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":"Glioblastoma","enrollment":52},{"nctId":"NCT02973789","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)","status":"COMPLETED","sponsor":"NovoCure GmbH","startDate":"2016-12","conditions":"Nonsmall Cell Lung Cancer, NSCLC","enrollment":291},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Pancreatic Cancer Resectable","enrollment":30},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT06114940","phase":"PHASE2","title":"Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)","status":"TERMINATED","sponsor":"Jinling Hospital, China","startDate":"2022-12-20","conditions":"Renal Cell Carcinoma (RCC)","enrollment":17},{"nctId":"NCT07110103","phase":"PHASE2","title":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-31","conditions":"SCLC, SCLC, Extensive Stage","enrollment":20},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT03774732","phase":"PHASE3","title":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-01-24","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4","enrollment":327},{"nctId":"NCT07410715","phase":"","title":"Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma (SWITCH)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-01","conditions":"HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery","enrollment":100},{"nctId":"NCT07408635","phase":"PHASE2","title":"IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-01-07","conditions":"Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)","enrollment":43},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","enrollment":15},{"nctId":"NCT03686202","phase":"PHASE2, PHASE3","title":"Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2018-11-30","conditions":"All Solid Tumors","enrollment":65},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT07332247","phase":"PHASE2","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-03","conditions":"Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma","enrollment":94},{"nctId":"NCT07381400","phase":"PHASE2","title":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06283238","phase":"","title":"Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2025-04-16","conditions":"GastroEsophageal Cancer","enrollment":""},{"nctId":"NCT06206733","phase":"PHASE3","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AskGene Pharma, Inc.","startDate":"2024-01-25","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":780},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT07077512","phase":"PHASE2","title":"Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)","enrollment":30},{"nctId":"NCT07350070","phase":"PHASE2","title":"TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-31","conditions":"HCC, Liver Cirrhosis, Portal Hypertension","enrollment":78},{"nctId":"NCT07340502","phase":"","title":"TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-31","conditions":"HCC","enrollment":364},{"nctId":"NCT07330050","phase":"PHASE2","title":"WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":31},{"nctId":"NCT07277777","phase":"PHASE2","title":"125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Malignant Tumors","enrollment":90},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06121505","phase":"PHASE2","title":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-03-01","conditions":"Lung Squamous Cell Carcinoma","enrollment":114},{"nctId":"NCT04157985","phase":"PHASE3","title":"Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dan Zandberg","startDate":"2019-11-15","conditions":"Advanced Solid Tumors, NSCLC, Bladder Cancer","enrollment":161},{"nctId":"NCT07263386","phase":"PHASE2","title":"A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-23","conditions":"Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT06154538","phase":"PHASE2","title":"Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-11-01","conditions":"Locally Advanced Colorectal Carcinoma","enrollment":170},{"nctId":"NCT06841679","phase":"PHASE2, PHASE3","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":778},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT06698250","phase":"PHASE2","title":"Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2024-12-18","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05057247","phase":"PHASE2","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Glenn J. Hanna","startDate":"2021-10-14","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer","enrollment":26},{"nctId":"NCT06558799","phase":"PHASE2","title":"LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NovoCure GmbH","startDate":"2024-10-14","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":69},{"nctId":"NCT03910660","phase":"PHASE1, PHASE2","title":"A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2019-02-12","conditions":"Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma","enrollment":98},{"nctId":"NCT04887870","phase":"PHASE2, PHASE3","title":"Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-29","conditions":"Advanced or Metastatic Solid Malignancies","enrollment":52},{"nctId":"NCT06896188","phase":"PHASE1","title":"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2025-09-22","conditions":"Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT07164690","phase":"PHASE2","title":"Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":"Esophageal Adenocarcinoma, Radiotherapy","enrollment":32},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT05509699","phase":"PHASE2","title":"Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2022-09-27","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT04997850","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Xinrui Zhu，MD","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor","enrollment":142},{"nctId":"NCT03708328","phase":"PHASE1","title":"A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-15","conditions":"Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":134},{"nctId":"NCT04225039","phase":"PHASE2","title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-06-23","conditions":"Glioblastoma","enrollment":39},{"nctId":"NCT07057089","phase":"PHASE2","title":"Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-07-01","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT06958419","phase":"PHASE2, PHASE3","title":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-05-01","conditions":"Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)","enrollment":286},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT07092696","phase":"PHASE2","title":"Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-01","conditions":"Cervical Cancer","enrollment":34},{"nctId":"NCT06865521","phase":"NA","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-02-21","conditions":"Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila","enrollment":22},{"nctId":"NCT06947694","phase":"PHASE2","title":"A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2025-07-02","conditions":"NSCLC Stage IV Without EGFR/ALK Mutation","enrollment":427},{"nctId":"NCT03984357","phase":"PHASE2","title":"Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-03-16","conditions":"Nasopharyngeal Carcinoma","enrollment":152},{"nctId":"NCT04907370","phase":"PHASE3","title":"PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":532},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT05451043","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-05","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer","enrollment":62},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT07015489","phase":"PHASE2","title":"Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"ESCC","enrollment":44},{"nctId":"NCT04082364","phase":"PHASE2, PHASE3","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2019-09-30","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer","enrollment":82},{"nctId":"NCT05944237","phase":"PHASE1, PHASE2","title":"HTL0039732 in Participants With Advanced Solid Tumours","status":"RECRUITING","sponsor":"Cancer Research UK","startDate":"2023-07-13","conditions":"Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms","enrollment":150},{"nctId":"NCT06767956","phase":"PHASE1, PHASE2","title":"Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Natalie Galanina","startDate":"2025-06-30","conditions":"Non Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT06988592","phase":"","title":"GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-23","conditions":"Advanced Biliary Tract Cancer","enrollment":100},{"nctId":"NCT06980389","phase":"PHASE2","title":"Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-05-31","conditions":"Immune Checkpoint Therapy, Radiotherapy, Metastatic Gastric Carcinoma","enrollment":176},{"nctId":"NCT06965231","phase":"PHASE2","title":"Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-01","conditions":"Melanoma of Skin, Acral Melanoma, Stage II Melanoma","enrollment":58},{"nctId":"NCT05130177","phase":"PHASE2","title":"Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma","status":"RECRUITING","sponsor":"Diwakar Davar","startDate":"2022-03-16","conditions":"Melanoma","enrollment":26},{"nctId":"NCT06957977","phase":"PHASE2","title":"A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhongguang Luo, MD","startDate":"2025-05-01","conditions":"Gastric Cancer, Cryoballoon Ablation","enrollment":42},{"nctId":"NCT06493552","phase":"PHASE2, PHASE3","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2025-03-15","conditions":"Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma","enrollment":700},{"nctId":"NCT06890624","phase":"PHASE2","title":"MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Colon Cancer (stage II & III)","enrollment":138},{"nctId":"NCT02936752","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Myelodysplastic Syndrome","enrollment":28},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06871527","phase":"PHASE1, PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-03-01","conditions":"Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib","enrollment":44},{"nctId":"NCT03236935","phase":"PHASE1","title":"Phase Ib of L-NMMA and Pembrolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-03","conditions":"Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT05576077","phase":"PHASE1","title":"A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Turnstone Biologics, Corp.","startDate":"2023-01-17","conditions":"Breast Cancer, Colorectal Cancer, Uveal Melanoma","enrollment":31},{"nctId":"NCT06858969","phase":"PHASE2","title":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-09","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT04777084","phase":"PHASE2","title":"The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2021-08-01","conditions":"Non-Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT03886311","phase":"PHASE2","title":"Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma","status":"RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2019-05-15","conditions":"Sarcoma","enrollment":200},{"nctId":"NCT05062980","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer","status":"TERMINATED","sponsor":"Genprex, Inc.","startDate":"2022-03-30","conditions":"Non Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT03190174","phase":"PHASE1, PHASE2","title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","status":"COMPLETED","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2017-08-24","conditions":"Ewing Sarcoma, PEComa, Epithelioid Sarcoma","enrollment":34},{"nctId":"NCT04271956","phase":"PHASE2","title":"Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation","status":"RECRUITING","sponsor":"German CLL Study Group","startDate":"2020-02-19","conditions":"Richter Transformation","enrollment":83},{"nctId":"NCT05214222","phase":"PHASE2","title":"Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-09-02","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT03869034","phase":"PHASE2","title":"HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-25","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06708650","phase":"NA","title":"Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guiping People's Hospital","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors","enrollment":50},{"nctId":"NCT03761914","phase":"PHASE1, PHASE2","title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2019-09-30","conditions":"Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer","enrollment":26},{"nctId":"NCT03769467","phase":"PHASE1, PHASE2","title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","status":"TERMINATED","sponsor":"Atara Biotherapeutics","startDate":"2019-02-19","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections","enrollment":12},{"nctId":"NCT04512534","phase":"PHASE2","title":"Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2020-11-13","conditions":"Peripheral T-cell Lymphoma","enrollment":51},{"nctId":"NCT06646666","phase":"PHASE2","title":"ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-01","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":35},{"nctId":"NCT05772455","phase":"PHASE1","title":"A Study of XZB-0004 in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2023-03-24","conditions":"Advanced Solid Tumor, NSCLC","enrollment":128},{"nctId":"NCT03340766","phase":"PHASE1","title":"Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-03-16","conditions":"Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":31},{"nctId":"NCT06643533","phase":"","title":"Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)","status":"NOT_YET_RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":15},{"nctId":"NCT06614140","phase":"PHASE1, PHASE2","title":"Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqker Biosciences, Inc.","startDate":"2022-11-24","conditions":"Cancer, Solid Tumor, Adult","enrollment":8},{"nctId":"NCT06137378","phase":"PHASE2","title":"European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-04-17","conditions":"Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Continuous PD-1 inhibitor therapy","genericName":"Continuous PD-1 inhibitor therapy","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses. Used for Cancer (specific tumor type under investigation in Canadian Cancer Trials Group phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}